Azacitidine as therapy for VEXAS syndrome
D
David P. Steensma
(1Ajax Therapeutics)
M
Mrinal M. Patnaik
(Division of Hematology, Department of Internal Medicine, Mayo Clinic)
Article Details
Journal
Blood
Volume / Issue
Vol. 146, Issue 12
Published
September 18, 2025
Pages
1380-1382
ISSN
0006-4971
Publisher
Elsevier BV
Authors (2)
D
David P. Steensma
1Ajax Therapeutics
M
Mrinal M. Patnaik
Division of Hematology, Department of Internal Medicine, Mayo Clinic
Related Articles from this Journal
NOTCHing the MSC-endothelial interplay in the HSC niche
Simón Méndez-Ferrer
Aug 2026
10.1182/blood.2026034119
Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals
Chang Xu, Xue Lv et al.
Aug 2026
10.1182/blood.2025031474
Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. <i>Blood</i> . 2022;140(15):1686-1701.
Aug 2026
10.1182/blood.2026035281
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Karthik Chetlapalli, Satoko Ito et al.
Aug 2026
10.1182/blood.2025032290
Granulopoiesis under attack by mutant IDH1
Hideyo Hirai
Aug 2026
10.1182/blood.2026034486